Novel 6xHis tagged foot-and-mouth disease virus vaccine bound to nanolipoprotein adjuvant via metal ions provides antigenic distinction and effective protective immunity
| Autor: | Teresa de los Santos, Paul D. Hoeprich, Elizabeth Rieder, Thomas G. Burrage, Luis L. Rodriguez, Fayna Diaz-San Segundo, Devendra K. Rai, Elizabeth A. Schafer |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Models
Molecular 0301 basic medicine Protein Conformation Lipoproteins Recombinant Fusion Proteins animal diseases viruses medicine.medical_treatment Monophosphoryl Lipid A Genome Viral Marker vaccine Biology Antibodies Viral Virus Microbiology 03 medical and health sciences Immune system Adjuvants Immunologic Antigen Virology Gene Order medicine Animals Antigens Viral Ions Viral Vaccine Viral Vaccines biochemical phenomena metabolism and nutrition biology.organism_classification Antibodies Neutralizing 030104 developmental biology Foot-and-Mouth Disease Virus Metals Foot-and-Mouth Disease Mutation Nanoparticles Foot-and-mouth disease virus Adjuvant Protein Binding |
| Zdroj: | Virology. 495:136-147 |
| ISSN: | 0042-6822 |
| Popis: | Here, we engineered two FMD viruses with histidine residues inserted into or fused to the FMDV capsid. Both 6xHis viruses exhibited growth kinetics, plaque morphologies and antigenic characteristics similar to wild-type virus. The 6xHis tag allowed one-step purification of the mutant virions by Co(2+) affinity columns. Electron microscopy and biochemical assays showed that the 6xHis FMDVs readily assembled into antigen: adjuvant complexes in solution, by conjugating with Ni(2+)-chelated nanolipoprotein and monophosphoryl lipid A adjuvant (MPLA:NiNLP). Animals Immunized with the inactivated 6xHis-FMDV:MPLA:NiNLP vaccine acquired enhanced protective immunity against FMDV challenge compared to virions alone. Induction of anti-6xHis and anti-FMDV neutralizing antibodies in the immunized animals could be exploited in the differentiation of vaccinated from infected animals needed for the improvement of FMD control measures. The novel marker vaccine/nanolipid technology described here has broad applications for the development of distinctive and effective immune responses to other pathogens of importance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect